An oral GLP-1 reported better weight loss than the semaglutide tablet in a head-to-head trial
Awaiting primary-source check
Trial results reported in July compared an oral GLP-1 against oral semaglutide directly, with the newer agent producing greater weight reduction. Like oral semaglutide, it requires no refrigeration, which coverage highlighted as an advantage for expanding access in countries where reliable cold chain storage is not available.
What this actually means
Head-to-head trials are worth far more than comparing separate studies, so this is a genuinely useful result rather than another press release.
The refrigeration point is the part most worth noticing, and it is almost always buried under the weight-loss percentage. Injectable GLP-1s need cold storage from factory to fridge. That is manageable in the UK and a serious obstacle across much of the world. A tablet that sits on a shelf changes who can realistically be treated.
For a UK reader it changes nothing today. Neither drug in this comparison is on the NHS for weight management, and the oral semaglutide tablet is private-only. But it is a good reminder that the most important thing about a medicine is often not how well it works, it is whether it can reach people.
Told first, next time
This story reached you late. A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.